Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CYTI spin-off to focus on prostate cancer

CYTI spin-off to focus on prostate cancer Ivor Royston, who is founder and president of the San Diego Regional Cancer Center, will be heading up a new company, as yet unnamed, to be spun out of Cytocare Inc.

CYTI (Aliso Viejo, Calif.) and the non-profit SDRCC, an affiliate of Sharp Healthcare, have entered into a memorandum of understanding to launch a company focused on urologic cancer, with an emphasis on prostate cancer.

CYTI will contribute a murine monoclonal antibody that

Read the full 812 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE